source
- Epilepsy drug from Ovid and Takeda receives fresh start under Perceptive-backed ventureAfter about 26 months since two Phase 3 trials failed, the epilepsy treatment candidate originally developed by Ovid Therapeutics and Takeda has been removed from their pipelines. Investment firm…
- Former Legend Biotech CEO Ying Huang appointed head of K2 TherapeuticsK2 Therapeutics announced that Ying Huang, who recently left his role as CEO of Legend Biotech, will now lead the young biotech company. The appointment comes just weeks after Legend announced Huan…